Abstract
INTRODUCTION Late-onset Alzheimer’s disease (AD) frequently co-occurs with cerebrovascular disease. We hypothesized that interactions between genes and cerebrovascular risk factors (CVRFs) contribute to AD risk.
METHODS Participants age 65 years or older from five multi-ethnic cohorts (N=14,669) were included in genome-wide association meta-analyses for AD including an interaction factor for a CVRF score created from body mass index, hypertension, heart disease, and diabetes. Significant gene level results were substantiated using neuropathological and gene expression data.
RESULTS At the gene-level, FMNL2 interacted with the CVRF score to significantly modify AD risk (p= 7.7×10-7). A SNP within FRMD4B, rs1498837, was nominally significant (p=7.95×10-7). Increased FMNL2 expression was significantly associated with brain infarcts and AD.
DISCUSSION FMNL2 is highly expressed in the brain and has been associated with ischemic stroke and failures in endosomal trafficking, a major pathway in AD pathology. The results highlight an interaction between FMNL2 and CVRFs on AD susceptibility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from the National Institute on Aging (NIA), by the National Institutes of Health (NIH) (1RF1AG054023, 5R37AG015473, RF1AG015473, R56AG051876) and the National Center for Advancing Translational Sciences NIH through Grant Number UL1TR001873 and TL1TR001875. The National Alzheimer's Coordinating Center is supported by U01AG016976. ROSMAP was supported by NIA grants P30AG10161, R01AG15819, R01AG17917, U01AG46152, U01AG61356.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Columbia University Medical Center
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data included in the paper can be accessed after request. Genetic and phenotype data for WHICAP can be requested:https://cumc.co1.qualtrics.com/jfe/form/SV_6x5rRy14B6vpoqN Genetic and phenotype data for EFIGA can be requested: https://cumc.co1.qualtrics.com/jfe/form/SV_dmck0uV3A91pmzb Genetic and phenotype data for ROSMAP can be requested: https://www.radc.rush.edu/ Genetic and phenotype data for NACC can be requested:https://www.alz.washington.edu/WEB/landingRequest.html, https://www.niagads.org/user/login?destination=data/request/new_request/
https://cumc.co1.qualtrics.com/jfe/form/SV_6x5rRy14B6vpoqN
https://cumc.co1.qualtrics.com/jfe/form/SV_dmck0uV3A91pmzb
https://www.alz.washington.edu/WEB/landingRequest.html
https://www.niagads.org/user/login?destination=data/request/new_request/
